CN106692189A - 一种保护肝脏的组合物 - Google Patents
一种保护肝脏的组合物 Download PDFInfo
- Publication number
- CN106692189A CN106692189A CN201710056575.9A CN201710056575A CN106692189A CN 106692189 A CN106692189 A CN 106692189A CN 201710056575 A CN201710056575 A CN 201710056575A CN 106692189 A CN106692189 A CN 106692189A
- Authority
- CN
- China
- Prior art keywords
- oil
- composition
- liver
- mouse
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 129
- 210000004185 liver Anatomy 0.000 title abstract description 81
- 230000002633 protecting effect Effects 0.000 title abstract description 13
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910003472 fullerene Inorganic materials 0.000 claims abstract description 32
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 25
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 17
- 150000004676 glycans Chemical class 0.000 claims abstract description 12
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 12
- 239000005017 polysaccharide Substances 0.000 claims abstract description 12
- 235000021466 carotenoid Nutrition 0.000 claims abstract description 11
- 150000001747 carotenoids Chemical class 0.000 claims abstract description 11
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 10
- 235000012754 curcumin Nutrition 0.000 claims abstract description 10
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 10
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 10
- 150000003505 terpenes Chemical class 0.000 claims abstract description 10
- 235000007586 terpenes Nutrition 0.000 claims abstract description 10
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 10
- 239000011709 vitamin E Substances 0.000 claims abstract description 10
- 229940046009 vitamin E Drugs 0.000 claims abstract description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 229930003935 flavonoid Natural products 0.000 claims abstract description 9
- 235000017173 flavonoids Nutrition 0.000 claims abstract description 9
- 150000002215 flavonoids Chemical class 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 239000004148 curcumin Substances 0.000 claims abstract description 8
- 229940109262 curcumin Drugs 0.000 claims abstract description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 7
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 7
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims abstract description 6
- 229950001002 cianidanol Drugs 0.000 claims abstract description 6
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 claims abstract description 5
- 108010024636 Glutathione Proteins 0.000 claims abstract description 5
- 102000003792 Metallothionein Human genes 0.000 claims abstract description 5
- 108090000157 Metallothionein Proteins 0.000 claims abstract description 5
- 229960003180 glutathione Drugs 0.000 claims abstract description 5
- 235000003969 glutathione Nutrition 0.000 claims abstract description 5
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 4
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 4
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 4
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 4
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 4
- 239000003921 oil Substances 0.000 claims description 42
- 235000019198 oils Nutrition 0.000 claims description 41
- 241000196324 Embryophyta Species 0.000 claims description 29
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 24
- 239000004006 olive oil Substances 0.000 claims description 15
- 235000008390 olive oil Nutrition 0.000 claims description 15
- 235000013793 astaxanthin Nutrition 0.000 claims description 12
- 239000000944 linseed oil Substances 0.000 claims description 10
- 150000003648 triterpenes Chemical class 0.000 claims description 10
- 235000021388 linseed oil Nutrition 0.000 claims description 9
- 235000012661 lycopene Nutrition 0.000 claims description 9
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 7
- 240000008397 Ganoderma lucidum Species 0.000 claims description 7
- 241000727169 Prinsepia utilis Species 0.000 claims description 7
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 7
- -1 phytosterol Chemical class 0.000 claims description 7
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims description 6
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 6
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 6
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 claims description 6
- 239000001168 astaxanthin Substances 0.000 claims description 6
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims description 6
- 229940022405 astaxanthin Drugs 0.000 claims description 6
- 239000001751 lycopene Substances 0.000 claims description 6
- 229960004999 lycopene Drugs 0.000 claims description 6
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 6
- 229930014669 anthocyanidin Natural products 0.000 claims description 5
- 150000001452 anthocyanidin derivatives Chemical class 0.000 claims description 5
- 235000008758 anthocyanidins Nutrition 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000005487 catechin Nutrition 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 235000019482 Palm oil Nutrition 0.000 claims description 4
- 235000013734 beta-carotene Nutrition 0.000 claims description 4
- 239000011648 beta-carotene Substances 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 229940087559 grape seed Drugs 0.000 claims description 4
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 4
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 4
- 235000008696 isoflavones Nutrition 0.000 claims description 4
- 239000002540 palm oil Substances 0.000 claims description 4
- 235000005875 quercetin Nutrition 0.000 claims description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 4
- 235000004936 Bromus mango Nutrition 0.000 claims description 3
- 235000014826 Mangifera indica Nutrition 0.000 claims description 3
- 240000007228 Mangifera indica Species 0.000 claims description 3
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 claims description 3
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 claims description 3
- 235000009184 Spondias indica Nutrition 0.000 claims description 3
- 244000269722 Thea sinensis Species 0.000 claims description 3
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 3
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 3
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 3
- 229960002747 betacarotene Drugs 0.000 claims description 3
- 235000021323 fish oil Nutrition 0.000 claims description 3
- 235000008397 ginger Nutrition 0.000 claims description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001285 quercetin Drugs 0.000 claims description 3
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 2
- 235000019489 Almond oil Nutrition 0.000 claims description 2
- 241001116389 Aloe Species 0.000 claims description 2
- 235000007689 Borago officinalis Nutrition 0.000 claims description 2
- 240000004355 Borago officinalis Species 0.000 claims description 2
- 241000251730 Chondrichthyes Species 0.000 claims description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 claims description 2
- 240000002045 Guettarda speciosa Species 0.000 claims description 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 2
- 240000006079 Schisandra chinensis Species 0.000 claims description 2
- 235000004433 Simmondsia californica Nutrition 0.000 claims description 2
- 244000044822 Simmondsia californica Species 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 2
- 241001506047 Tremella Species 0.000 claims description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 2
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 2
- 235000019498 Walnut oil Nutrition 0.000 claims description 2
- 239000008168 almond oil Substances 0.000 claims description 2
- 235000011399 aloe vera Nutrition 0.000 claims description 2
- 239000010775 animal oil Substances 0.000 claims description 2
- 239000010474 borage seed oil Substances 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims description 2
- 150000001721 carbon Chemical group 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 239000003240 coconut oil Substances 0.000 claims description 2
- 235000019864 coconut oil Nutrition 0.000 claims description 2
- 235000008524 evening primrose extract Nutrition 0.000 claims description 2
- 239000010475 evening primrose oil Substances 0.000 claims description 2
- 229940089020 evening primrose oil Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 229940025902 konjac mannan Drugs 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 239000001944 prunus armeniaca kernel oil Substances 0.000 claims description 2
- 235000021283 resveratrol Nutrition 0.000 claims description 2
- 229940016667 resveratrol Drugs 0.000 claims description 2
- 239000010667 rosehip oil Substances 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 229940057910 shea butter Drugs 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000008170 walnut oil Substances 0.000 claims description 2
- 239000010698 whale oil Substances 0.000 claims description 2
- 239000010497 wheat germ oil Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 235000005881 Calendula officinalis Nutrition 0.000 claims 1
- 240000001432 Calendula officinalis Species 0.000 claims 1
- 241000270722 Crocodylidae Species 0.000 claims 1
- 235000014443 Pyrus communis Nutrition 0.000 claims 1
- 244000273928 Zingiber officinale Species 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 claims 1
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 39
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 39
- 239000008280 blood Substances 0.000 abstract description 34
- 210000004369 blood Anatomy 0.000 abstract description 34
- 230000000694 effects Effects 0.000 abstract description 30
- 230000006378 damage Effects 0.000 abstract description 7
- 230000003908 liver function Effects 0.000 abstract description 7
- 150000003254 radicals Chemical class 0.000 abstract description 5
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 abstract 1
- 235000010208 anthocyanin Nutrition 0.000 abstract 1
- 239000004410 anthocyanin Substances 0.000 abstract 1
- 229930002877 anthocyanin Natural products 0.000 abstract 1
- 150000004636 anthocyanins Chemical class 0.000 abstract 1
- 235000017471 coenzyme Q10 Nutrition 0.000 abstract 1
- 229940110767 coenzyme Q10 Drugs 0.000 abstract 1
- 230000002000 scavenging effect Effects 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 83
- VZGDMQKNWNREIO-UHFFFAOYSA-N carbon tetrachloride Substances ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 59
- 239000002504 physiological saline solution Substances 0.000 description 41
- 238000003304 gavage Methods 0.000 description 28
- 230000002496 gastric effect Effects 0.000 description 26
- 238000001802 infusion Methods 0.000 description 26
- 208000019423 liver disease Diseases 0.000 description 24
- 238000001514 detection method Methods 0.000 description 17
- 231100000753 hepatic injury Toxicity 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000007924 injection Substances 0.000 description 14
- 238000002347 injection Methods 0.000 description 14
- 239000007928 intraperitoneal injection Substances 0.000 description 14
- 230000001681 protective effect Effects 0.000 description 13
- 230000034994 death Effects 0.000 description 11
- 238000010586 diagram Methods 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 206010067125 Liver injury Diseases 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 150000001514 astaxanthins Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000000630 rising effect Effects 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 241000234314 Zingiber Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 150000002664 lycopenes Chemical class 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 150000001336 alkenes Chemical class 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 231100000832 liver cell necrosis Toxicity 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 240000000400 Balanites maughamii Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 244000000626 Daucus carota Species 0.000 description 1
- 235000002767 Daucus carota Nutrition 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- RDMQPKIDHAFXKA-JNORPAGFSA-N Ganoderic Acid Am1 Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC(=O)C1=C2C(=O)C[C@]2(C)[C@@H]([C@@H](CC(=O)CC(C)C(O)=O)C)CC(=O)[C@]21C RDMQPKIDHAFXKA-JNORPAGFSA-N 0.000 description 1
- 229930182735 Ganoderic acid Natural products 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 101001031591 Mus musculus Heart- and neural crest derivatives-expressed protein 2 Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- CWEZAWNPTYBADX-UHFFFAOYSA-N Procyanidin Natural products OC1C(OC2C(O)C(Oc3c2c(O)cc(O)c3C4C(O)C(Oc5cc(O)cc(O)c45)c6ccc(O)c(O)c6)c7ccc(O)c(O)c7)c8c(O)cc(O)cc8OC1c9ccc(O)c(O)c9 CWEZAWNPTYBADX-UHFFFAOYSA-N 0.000 description 1
- 241001199649 Senegalia erubescens Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 235000021302 avocado oil Nutrition 0.000 description 1
- 239000008163 avocado oil Substances 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 150000001579 beta-carotenes Chemical class 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002091 nanocage Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920002414 procyanidin Polymers 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000007348 radical reaction Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种保护肝脏的组合物,其包括均匀分散在食用油中的富勒烯,还包括均匀分散在所述食用油中的维生素C、维生素E、儿茶素、α‑硫辛酸、花青素、姜黄素、类胡萝卜素、植物多酚类、植物多糖类、动植物萜类、植物甾醇类、植物黄酮类、SOD、辅酶Q10、谷胱甘肽、乳铁蛋白和金属硫蛋白中的至少一种。该组合物可以有效保护肝脏,降低不利因素对小鼠肝脏造成的损伤,使肝脏功能的血液指标趋于正常范围,并具有良好的清除自由基的效果,可以对肝脏进行“清理”,改善肝脏内的氧化还原水平。
Description
技术领域
本发明涉及医药领域,特别涉及一种保护肝脏的组合物。
背景技术
肝脏是维持机体生命活动的重要器官,它不仅参与机体消化、排泄、解毒、合成以及免疫等多种生物化学过程,而且在机体糖类、蛋白质、脂肪的代谢方面发挥至关重要的作用。肝脏作为机体代谢有毒物质的主要器官,一旦短时间内摄入大量有毒的化学物质超过肝脏的承受范围,就会引起肝脏的急、慢性肝损伤。肝损伤的具体表现包括肝细胞结构被破坏、肝细胞形态明显变形、细胞有浸润现象、细胞核数量明显减少,还包括谷丙转氨酶(ALT)活性增高和超氧化物歧化酶(SOD)含量降低。由肝损伤引起的肝功能紊乱是多种肝脏病变的共同病理基础,是多种严重肝脏疾病的发生、发展及最终走向肝功能衰竭的病因。因此,治疗肝损伤对研究急慢性肝病、肝炎、肝硬化及肝癌的防治具有重要意义。
现有技术中大部分药物无法避免用药后的副作用,比如:联苯双酯服用后可能会有口干、恶心、皮疹等反应,停药后还会出现转氨酶反跳的现象;强力宁服用后可能会引起胸闷、浮肿、轻度血压升高等现象。
富勒烯是除石墨、金刚石和无定型碳之外碳元素的另一种同素异形体。这类物质指的是由碳原子组成的笼状结构,其含量最多的分子是C60,然后是C70、C84,其次是含量相对较少的C76、C78、C82等。
公开于该背景技术部分的信息仅仅旨在增加对本发明的总体背景的理解,而不应当被视为承认或以任何形式暗示该信息构成已为本领域一般技术人员所公知的现有技术。
发明内容
本发明目的在于提供一种新的保护肝脏的组合物,该组合物可以有效保护肝脏,降低不利因素对小鼠肝脏造成的损伤,使受损肝脏功能的血液指标趋于正常范围,并具有良好的清除自由基的效果,可以对肝脏进行“清理”,改善肝脏内的氧化还原水平。
为了实现上述发明目的,本发明提供了如下技术方案:
一种保护肝脏的组合物,包括均匀分散在食用油中的富勒烯,还包括均匀分散在所述食用油中的维生素C、维生素E、儿茶素、α-硫辛酸、花青素、姜黄素、类胡萝卜素、植物多酚类、植物多糖类、动植物萜类、植物甾醇类、植物黄酮类、SOD、辅酶Q10、谷胱甘肽、乳铁蛋白和金属硫蛋白中的至少一种。
上述组合物在另一种实施方式中,所述富勒烯包括一种或多种通式为C2m的由碳原子组成的笼状结构,30≤m≤60,例如:C60,C70,C84等。
上述组合物在另一种实施方式中,所述富勒烯包括C60、C70和C84中的至少一种。
上述组合物在另一种实施方式中,所述食用油包括植物油、动物油和矿物油中的至少一种,可选的所述食用油包括橄榄油、亚麻籽油、青刺果油、油菜籽油、甜杏仁油、葵花油、红花籽油、葡萄籽油、月见草油、琉璃苣籽油、当归油、生姜油、荷荷巴油、核桃油、鳄梨油、芒果油、蓖麻油、杏仁油、乳木果油、玫瑰果油、椰子油、棕榈油、谷糠油、小麦胚芽油、金盏花油、芦荟油、棕榈油、阿甘油、牛油、羊油、猪油、鲸油和鱼油中的至少一种。
上述组合物在另一种实施方式中,所述类胡萝卜素包括虾青素、β-胡萝卜素和茄红素中的至少一种;植物多酚类包括茶多酚、葡萄籽多酚、苹果多酚和白藜芦醇中的至少一种;所述植物多糖类包括茶多糖、枸杞多糖、魔芋甘露聚糖、银杏叶多糖、海藻多糖、香菇多糖、银耳多糖、灵芝多糖、黑木耳多糖和茯苓多糖中的至少一种;所述动植物萜类包括鲨鱼油三萜类、甘草三萜类、五味子三萜类和灵芝三萜类中的至少一种;所述植物甾醇类包括大豆甾醇;所述植物黄酮类包括大豆异黄酮和槲皮素中的至少一种。
上述组合物在另一种实施方式中,所述富勒烯在食用油中的浓度为0.001-1.0g/ml,可选的为0.001-0.01g/ml,还可选的为0.003-0.006g/ml,还可选的为0.1-0.7g/ml。
上述组合物在另一种实施方式中,维生素C、维生素E、儿茶素、α-硫辛酸、花青素、姜黄素、类胡萝卜素、植物多酚类、植物多糖类、动植物萜类、植物甾醇类、植物黄酮类、SOD、辅酶Q10、谷胱甘肽、乳铁蛋白和/或金属硫蛋白在每100ml食用油中的含量为0.001mg-10mg,可选的为0.003-5mg,还可选0.005-3mg。
上述组合物在另一种实施方式中,包括均匀分散在食用油中的以下四种组分:
组分1:富勒烯;
组分2:维生素E、维生素C、植物多酚类和植物黄酮类中的至少一种;
组分3:类胡萝卜素、茄红素和虾青素中的至少一种;以及
组分4:硫辛酸、谷胱甘肽、动植物萜类、植物多糖和辅酶Q10中的至少一种。
其中:富勒烯是稳定的抗氧化剂,其将自由基电子和能量转移给体内生物大分子;维生素E、维生素C、植物多酚和植物黄酮将自身的氢与自由基反应从而被降解;茄红素、虾青素和类胡萝卜素是接受自由基的能量来实现抗氧化;动植物萜类、植物多糖、辅酶Q10是优良的免疫调节剂和脂质过氧化物抑制剂,在人类身体细胞内参与能量制造及活化。几种不同作用方式的抗氧化剂,对保护肝脏起到协同增效的功效。
本发明还提供了上述组合物在制备保护肝脏的药品或保健品中的应用。
与现有技术相比,本发明具有如下有益效果:
1、本发明组合物均匀分散在食用油中形成均一稳定的透明溶液,组合物中各种组分形成特定的搭配,可以协同增效的保护肝脏,降低不利因素对小鼠肝脏造成的损伤,使肝脏功能的血液指标趋于正常范围;
2、本发明组合物进入肝脏后,具有良好的抗氧化、清除自由基的效果,可以对肝脏进行“清理”,改善肝脏内的氧化还原水平。
附图说明
图1是实施例1中各组小鼠的肝脏病理切片H&E染色对比图。
图2是实施例1中各组小鼠血液中的SOD活性的对比图。
图3是实施例1中各组小鼠血液中的肝损伤指标谷丙转氨酶活性的对比图。
图4是实施例2中各组小鼠的肝脏病理切片H&E染色对比图。
图5是实施例2中各组小鼠血液中的SOD活性的对比图。
图6是实施例2中各组小鼠血液中的肝损伤指标谷丙转氨酶活性的对比图。
图7是实施例3中各组小鼠的肝脏病理切片H&E染色对比图。
图8是实施例3中各组小鼠血液中的SOD活性的对比图。
图9是实施例3中各组小鼠血液中的肝损伤指标谷丙转氨酶活性的对比图。
图10是实施例4中各组小鼠的肝脏病理切片H&E染色对比图。
图11是实施例4中各组小鼠血液中的SOD活性的对比图。
图12是实施例4中各组小鼠血液中的肝损伤指标谷丙转氨酶活性的对比图。
图13是实施例5中各组小鼠的肝脏病理切片H&E染色对比图。
图14是实施例5中各组小鼠血液中的SOD活性的对比图。
图15是实施例5中各组小鼠血液中的肝损伤指标谷丙转氨酶活性的对比图。
具体实施方式
下面结合附图,对本发明的具体实施方式进行详细描述,但应当理解本发明的保护范围并不受具体实施方式的限制。
以下实施例中采用球磨或超声或超声球磨相结合的方式加快各组分在食用油中的分散速度,使各组分能达到均匀分散在相应食用油中的目的即可。
以下实施例中采用涉及多种组分,现对其介绍如下:
维生素C、维生素E:都是常见维生素。
辅酶Q10:化学式C59H90O4,CAS号303-98-0,是一种脂溶性抗氧化剂。
茄红素:化学式C40H56,CAS号502-65-8,主要存在于茄科植物西红柿的成熟果实中,它是目前在自然界的植物中被发现的最强抗氧化剂之一。
虾青素:化学式C40H52O4,CAS号472-61-7,是一种类胡萝卜素。
姜黄素:分子式C21H20O6,CAS号458-37-7,是从姜科、天南星科中的一些植物的根茎中提取的一种化学成分。
花青素:分子式C15H11O6,CAS号13306-05-3,是一种水溶性色素。
β-胡萝卜素:分子式C40H56,它是自然界中最普遍存在也是最稳定的天然色素。绿色蔬菜、甘薯、胡萝卜、菠菜、木瓜、芒果等皆存有丰富的β—胡萝卜素,β—胡萝卜素是一种抗氧化剂。
槲皮素:化学式C15H10O7,具有抗氧化作用。
茶多酚:CAS号84650-60-2,其是茶叶中多酚类物质的总称,以下实施例使用的茶多酚中儿茶素的质量百分比为98%(HPLC)。
葡萄籽多酚:即葡萄籽提取物,其CAS号为84929-27-1,以下实施例使用的葡萄籽多酚中原花青素含量≥95%。
大豆甾醇:CAS号83-48-7,为大豆油中的主要甾醇之一,纯度90%以上。
大豆异黄酮:CAS号574-12-9,提取自大豆中。
人参皂苷:CAS号90045-38-8,为五加科植物人参的干燥根提取物。
灵芝多糖:提取自100%椴木灵芝子实体,主要成分是多糖,三萜,糖肽。
灵芝孢子油:灵芝孢子油纯度达100%。产品富含三萜类灵芝酸、灵芝三萜、不饱和脂肪酸及微量元素等灵芝特有活性成分,具有增强机体免疫力、抗辐射、保肝养肝、辅助治疗肿瘤、补益心气、安神活血等保健功效。
实施例1
1、组合物的制备
将0.6g富勒烯C60、1g维生素E、0.1g辅酶Q10、0.05g虾青素和0.006g茶多酚、0.03g姜黄素,0.005g茄红素均匀分散在99.0ml的橄榄油中,获得组合物1。
2、实验对象
取6周大的ICR小鼠70只随机的平均分为7组,分别为组合物1+生理盐水组、橄榄油+生理盐水组、联苯双酯+生理盐水组、组合物1+CCl4组、橄榄油+CCl4组、联苯双酯+CCl4组和水+CCl4组。
3、实验方法
组合物1+生理盐水组:将组合物1灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束组合物1的2周的灌胃给药后对小鼠进行腹腔注射生理盐水,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD(超氧化物歧化酶)、ALT(谷丙转氨酶)的检测;
橄榄油+生理盐水组:将橄榄油灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束橄榄油的2周的灌胃给药后对小鼠进行腹腔注射生理盐水,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
联苯双酯+生理盐水组:将联苯双酯灌胃给药,给药剂量为3mg/ml的联苯双酯溶液150微升连续灌胃2周;结束联苯双酯的2周的灌胃给药后对小鼠进行腹腔注射生理盐水,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
组合物1+CCl4组:将组合物1灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束组合物1的2周的灌胃给药后对小鼠进行腹腔注射CCl4,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
橄榄油+CCl4组:将橄榄油灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束橄榄油的2周的灌胃给药后对小鼠进行腹腔注射CCl4,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
联苯双酯+CCl4组:将联苯双酯灌胃给药,给药剂量为3mg/ml的联苯双酯溶液150微升连续灌胃2周;结束联苯双酯的2周的灌胃给药后对小鼠进行腹腔注射CCl4,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
水+CCl4组:将水灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束水的2周的灌胃给药后对小鼠进行腹腔注射CCl4,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测。
以上SOD和ALT的检测均采用商业化试剂盒进行检测。SOD检测试剂盒的货号:A001-1,厂家:南京建成生物。ALT检测试剂盒的厂家:英科新创(厦门)科技有限公司。
4、实验结果
从肝脏病理切片检测结果和血液中SOD、ALT的检测结果中观察组合物1在急性肝损伤模型中对肝脏的保护作用,结果如下:
图1A是组合物1+生理盐水组的小鼠肝脏H&E染色图;图1B是组合物1+CCl4组的小鼠肝脏H&E染色图;图1C是橄榄油+生理盐水组的小鼠肝脏H&E染色图;图1D是橄榄油+CCl4组的小鼠肝脏H&E染色图;图1E是联苯双酯+生理盐水组的小鼠肝脏H&E染色图;图1F是联苯双酯+CCl4组的小鼠肝脏H&E染色图;图1G是水+CCl4组的小鼠肝脏H&E染色图。通过图1D和图1G可以看出,没有灌胃组合物1或联苯双酯、但注射了CCl4的小鼠肝损伤明显,肝细胞呈片状坏死。图1B中可以看出,灌胃了组合物1、也注射了CCl4的小鼠的肝脏损伤小得多,从而显示了组合物1对肝脏的保护作用。同时通过图1B和图1F的对比也可以看出,组合物1对肝脏的保护效果要优于阳性对照联苯双酯的保护作用。
通过图2、图3可以看出组合物1可以显著抑制CCl4引起的ALT水平的升高,从而使肝脏功能损伤较小,发挥其保肝护肝的作用。同时,灌胃组合物1并且注射了CCl4的小鼠血液中SOD含量低,表明小鼠体内自由基含量低,说明组合物1起到了护肝的作用。
实施例2
1、组合物的制备
将0.3g富勒烯C60、3g维生素E、0.07g虾青素、0.3g辅酶Q10,0.006g茶多酚、0.005g茄红素、0.01g大豆异黄酮和0.05g灵芝孢子油均匀分散在99.0ml的亚麻籽油中,获得组合物2。
2、实验对象
取6周大的ICR小鼠70只随机的平均分为7组,分别为组合物2+生理盐水组、亚麻籽油+生理盐水组、联苯双酯+生理盐水组、组合物2+CCl4组、亚麻籽油+CCl4组、联苯双酯+CCl4组和水+CCl4组。
3、实验方法
采用与实施例1相似的方法,仅对所加物质做适应性改变,即:组合物2+生理盐水组和组合物2+CCl4组中使用的是组合物2,其余条件均不变;亚麻籽油+生理盐水组和亚麻籽油+CCl4组中使用的是亚麻籽油,其余条件均不变。
4、实验结果
从病理检测结果和血液中SOD、ALT的检测结果中观察组合物2在急性肝损伤模型中对肝脏的保护作用,结果如下:
图4A是组合物2+生理盐水组的小鼠肝脏H&E染色图;图4B是组合物2+CCl4组的小鼠肝脏H&E染色图;图4C是亚麻籽油+生理盐水组的小鼠肝脏H&E染色图;图4D是亚麻籽油+CCl4组的小鼠肝脏H&E染色图;图4E是联苯双酯+生理盐水组的小鼠肝脏H&E染色图;图4F是联苯双酯+CCl4组的小鼠肝脏H&E染色图;图4G是水+CCl4组的小鼠肝脏H&E染色图。通过图4D和图4G可以看出,没有灌胃组合物2或联苯双酯、但注射了CCl4的小鼠肝损伤明显,肝细胞呈片状坏死。图4B中可以看出,灌胃了组合物2、也注射了CCl4的小鼠的肝脏损伤小得多,从而显示了组合物2对肝脏的保护作用。同时通过图4B和图4F的对比也可以看出,组合物2对肝脏的保护效果要优于阳性对照联苯双酯的保护作用。
通过图5、图6可以看出组合物2可以显著抑制CCl4引起的ALT水平的升高,从而使肝脏功能损伤较小,发挥其保肝护肝的作用;同时,灌胃组合物2并且注射了CCl4的小鼠血液中SOD含量低,表明小鼠体内自由基含量低,说明组合物起到了护肝的作用。
实施例3
1、组合物的制备
将0.5g富勒烯C60、2g维生素E、0.06g虾青素,0.4g辅酶Q10,0.01g花青素、0.01g姜黄素、0.05g灵芝多糖、0.02g大豆甾醇和0.01gβ-胡萝卜素均匀分散在99ml的青刺果油中,获得组合物3。
2、实验对象
取6周大的ICR小鼠70只随机的平均分为7组,分别为组合物3+生理盐水组、青刺果油+生理盐水组、联苯双酯+生理盐水组、组合物3+CCl4组、青刺果油+CCl4组、联苯双酯+CCl4组和水+CCl4组。
3、实验方法
采用与实施例1相似的方法,仅对所加物质做适应性改变,即:组合物3+生理盐水组和组合物3+CCl4组中使用的是组合物3,其余条件均不变;青刺果油+生理盐水组和青刺果油+CCl4组中使用的是青刺果油,其余条件均不变。
4、实验结果
从病理检测结果和血液中SOD、ALT的检测结果中观察组合物3在急性肝损伤模型中对肝脏的保护作用,结果如下:
图7A是组合物3+生理盐水组的小鼠肝脏H&E染色图;图7B是组合物3+CCl4组的小鼠肝脏H&E染色图;图7C是青刺果油+生理盐水组的小鼠肝脏H&E染色图;图7D是青刺果油+CCl4组的小鼠肝脏H&E染色图;图7E是联苯双酯+生理盐水组的小鼠肝脏H&E染色图;图7F是联苯双酯+CCl4组的小鼠肝脏H&E染色图;图7G是水+CCl4组的小鼠肝脏H&E染色图。通过图7D和图7G可以看出,没有灌胃组合物3或联苯双酯、但注射了CCl4的小鼠肝损伤明显,肝细胞呈片状坏死。图7B中可以看出,灌胃了组合物3、也注射了CCl4的小鼠的肝脏损伤小得多,从而显示了组合物3对肝脏的保护作用。同时通过图7B和图7F的对比也可以看出,组合物3对肝脏的保护效果要优于阳性对照联苯双酯的保护作用。
通过图8、图9可以看出组合物3可以显著抑制CCl4引起的ALT水平的升高,从而使肝脏功能损伤较小,发挥其保肝护肝的作用;同时,灌胃组合物3并且注射了CCl4的小鼠血液中SOD含量低,表明小鼠体内自由基含量低,说明组合物起到了护肝的作用。
实施例4
1、组合物的制备
将0.4g富勒烯C70、1.5g维生素E、0.08g虾青素、0.3g辅酶Q10、0.001g葡萄籽多酚、0.007g灵芝多糖、0.008g人参皂苷、0.05g姜黄素和0.01g槲皮素均匀分散在99ml的大豆油中,获得组合物4。
2、实验对象
取6周大的ICR小鼠50只随机的平均分为5组,分别为组合物4+生理盐水组、联苯双酯+生理盐水组、组合物4+CCl4组、联苯双酯+CCl4组和水+CCl4组。
3、实验方法
采用与实施例1相似的方法,仅所加物质做适应性改变,即:组合物4+生理盐水组和组合物4+CCl4组中使用的是组合物4,其余条件均不变。
4、实验结果
从病理检测结果和血液中SOD、ALT的检测结果中观察组合物4在急性肝损伤模型中对肝脏的保护作用,结果如下:
图10A是组合物4+生理盐水组的小鼠肝脏H&E染色图;图10B是组合物4+CCl4组的小鼠肝脏H&E染色图;图10C是联苯双酯+生理盐水组的小鼠肝脏H&E染色图;图10D是联苯双酯+CCl4组的小鼠肝脏H&E染色图;图10E是水+CCl4组的小鼠肝脏H&E染色图。通过图10E可以看出,没有灌胃组合物4或联苯双酯、但注射了CCl4的小鼠肝损伤明显,肝细胞呈片状坏死。图10B中可以看出,灌胃了组合物4、也注射了CCl4的小鼠的肝脏损伤小得多,从而显示了组合物4对肝脏的保护作用。同时通过图10B和图10D的对比也可以看出,组合物4对肝脏的保护效果要优于阳性对照联苯双酯的保护作用。
通过图11、图12可以看出组合物4可以显著抑制CCl4引起的ALT水平的升高,从而使肝脏功能损伤较小,发挥其保肝护肝的作用;同时,SOD含量低,表明小鼠体内自由基含量低,说明组合物起到了护肝的作用。
实施例5
1、组合物的制备
将0.4g富勒烯C60、0.1g维生素E、0.01g茶多酚、0.01g辅酶Q10、0.05g茄红素、0.05g虾青素和0.05g姜黄素均匀分散在99.0ml的橄榄油中,获得混合物5。
将0.4g富勒烯均匀分散在99.0ml橄榄油中,得纯富勒烯油。
将0.1g维生素E、0.01g茶多酚、0.01g辅酶Q10、0.05g茄红素、0.05g虾青素和0.05g姜黄素均匀分散在99.0ml的橄榄油中,得其他混合物。
2、实验对象
取6周大的ICR小鼠70只随机的平均分为7组,分别为组合物5+生理盐水组、纯富勒烯油+生理盐水组、其他混合物+生理盐水组、组合物5+CCl4组、纯富勒烯油+CCl4组、纯混合物+CCl4组和水+CCl4组。
3、实验方法
组合物5+生理盐水组:将组合物5灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束组合物5的2周的灌胃给药后对小鼠进行腹腔注射生理盐水,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
纯富勒烯油+生理盐水组:将纯富勒烯油灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束纯富勒烯油的2周的灌胃给药后对小鼠进行腹腔注射生理盐水,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
其他混合物+生理盐水组:将其他混合物灌胃给药,给药剂量为5ml/kg连续灌胃2周;结束其他混合物的2周的灌胃给药后对小鼠进行腹腔注射生理盐水,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
组合物5+CCl4组:将组合物5灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束组合物5的2周的灌胃给药后对小鼠进行腹腔注射CCl4,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
纯富勒烯油+CCl4组:将纯富勒烯油灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束纯富勒烯油的2周的灌胃给药后对小鼠进行腹腔注射CCl4,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
其他混合物+CCl4组:将其他混合物灌胃给药,给药剂量为5ml/kg连续灌胃2周;结束其他混合物的2周的灌胃给药后对小鼠进行腹腔注射CCl4,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测;
水+CCl4组:将水灌胃给药,给药剂量为5ml/kg,连续灌胃2周;结束水的2周的灌胃给药后对小鼠进行腹腔注射CCl4,注射剂量为1ml/kg,16h后处死小鼠并对其做肝脏病理切片和血液中SOD、ALT的检测。
4、实验结果
从病理检测结果和血液中SOD、ALT的检测结果中观察组合物5在急性肝损伤模型中对肝脏的保护作用,结果如下:
图13A是组合物5+生理盐水组的小鼠肝脏H&E染色图;图13B是组合物5+CCl4组的小鼠肝脏H&E染色图;图13C是纯富勒烯油+生理盐水组的小鼠肝脏H&E染色图;图13D是纯富勒烯油+CCl4组的小鼠肝脏H&E染色图;图13E是其他混合物+生理盐水组的小鼠肝脏H&E染色图;图13F是其他混合物+生理盐水组的小鼠肝脏H&E染色图,图13G是生理盐水+CCl4组的小鼠肝脏H&E染色图。从图13B、图13D和图13F的H&E染色中可以明显看出注射CCl4后,对肝脏的保护效果最好的是组合物5,其次为纯富勒烯油,其他混合物对肝脏的保护效果不是很明显。
通过图14、图15可以看出组合物5可以显著抑制CCl4引起的ALT水平的升高,从而使肝脏功能损伤较小,发挥其保肝护肝的作用。同时,灌胃组合物5并且注射了CCl4的小鼠血液中SOD含量低,表明小鼠体内自由基含量低,说明组合物起到了护肝的作用。并且组合物5抑制ALT水平升高、降低SOD含量的效果显著好于纯富勒烯油作用和其他组合物作用的简单加和,即组合物5中的富勒烯油和其他组合物的搭配对保护肝脏发挥了协同增效的作用
前述对本发明的具体示例性实施方案的描述是为了说明和例证的目的。这些描述并非想将本发明限定为所公开的精确形式,并且很显然,根据上述教导,可以进行很多改变和变化。对示例性实施例进行选择和描述的目的在于解释本发明的特定原理及其实际应用,从而使得本领域的技术人员能够实现并利用本发明的各种不同的示例性实施方案以及各种不同的选择和改变。本发明的范围意在由权利要求书及其等同形式所限定。
Claims (10)
1.一种保护肝脏的组合物,其特征在于,包括均匀分散在食用油中的富勒烯,还包括均匀分散在所述食用油中的维生素C、维生素E、儿茶素、α-硫辛酸、花青素、姜黄素、类胡萝卜素、植物多酚类、植物多糖类、动植物萜类、植物甾醇类、植物黄酮类、SOD、辅酶Q10、谷胱甘肽、乳铁蛋白和金属硫蛋白中的至少一种。
2.如权利要求1所述的组合物,其特征在于,所述富勒烯包括一种或多种通式为C2m的由碳原子组成的笼状结构,30≤m≤60。
3.如权利要求2所述的组合物,其特征在于,所述富勒烯包括C60、C70和C84中的至少一种。
4.如权利要求1所述的组合物,其特征在于,所述食用油包括植物油、动物油和矿物油中的至少一种,可选的所述食用油包括橄榄油、亚麻籽油、青刺果油、油菜籽油、甜杏仁油、葵花油、红花籽油、葡萄籽油、月见草油、琉璃苣籽油、当归油、生姜油、荷荷巴油、核桃油、鳄梨油、芒果油、蓖麻油、杏仁油、乳木果油、玫瑰果油、椰子油、棕榈油、谷糠油、小麦胚芽油、金盏花油、芦荟油、棕榈油、阿甘油、牛油、羊油、猪油、鲸油和鱼油中的至少一种。
5.如权利要求1所述的组合物,其特征在于,所述类胡萝卜素包括虾青素、β-胡萝卜素和茄红素中的至少一种;植物多酚类包括茶多酚、葡萄籽多酚、苹果多酚和白藜芦醇中的至少一种;所述植物多糖类包括茶多糖、枸杞多糖、魔芋甘露聚糖、银杏叶多糖、海藻多糖、香菇多糖、银耳多糖、灵芝多糖、黑木耳多糖和茯苓多糖中的至少一种;所述动植物萜类包括鲨鱼油三萜类、甘草三萜类、五味子三萜类和灵芝三萜类中的至少一种;所述植物甾醇类包括大豆甾醇;所述植物黄酮类包括大豆异黄酮和槲皮素中的至少一种。
6.如权利要求1所述的组合物,其特征在于,所述富勒烯在食用油中的浓度为0.001-1.0g/ml,可选的为0.001-0.01g/ml,还可选的为0.003-0.006g/ml,还可选的为0.1-0.7g/ml。
7.如权利要求1所述的组合物,其特征在于,维生素C、维生素E、儿茶素、α-硫辛酸、花青素、姜黄素、类胡萝卜素、植物多酚类、多糖类、萜类、植物甾醇类、黄酮类、SOD、辅酶Q10、谷胱甘肽、乳铁蛋白和/或金属硫蛋白在每100ml食用油中的含量为0.001mg-10mg,可选的为0.003-5mg,还可选0.005-3mg。
8.如权利要求1所述的组合物,其特征在于,包括均匀分散在食用油中的以下四种组分:
组分1:富勒烯;
组分2:维生素E、维生素C、植物多酚类和植物黄酮类中的至少一种;
组分3:类胡萝卜素、茄红素和虾青素中的至少一种;以及
组分4:硫辛酸、谷胱甘肽、动植物萜类、植物多糖和辅酶Q10中的至少一种。
9.如权利要求1所述的组合物,其特征在于,包括均匀分散在食用油中的:富勒烯,维生素E,虾青素和辅酶Q10。
10.一种权利要求1-9之一所述组合物在制备保护肝脏的药品或保健品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710056575.9A CN106692189A (zh) | 2017-01-25 | 2017-01-25 | 一种保护肝脏的组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710056575.9A CN106692189A (zh) | 2017-01-25 | 2017-01-25 | 一种保护肝脏的组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106692189A true CN106692189A (zh) | 2017-05-24 |
Family
ID=58909047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710056575.9A Pending CN106692189A (zh) | 2017-01-25 | 2017-01-25 | 一种保护肝脏的组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106692189A (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108720018A (zh) * | 2018-06-27 | 2018-11-02 | 中科赛可瑞(大连)生物科技有限公司 | 一种含姜黄素的肝脏保健组合物及其方法和应用 |
CN108813436A (zh) * | 2018-07-10 | 2018-11-16 | 曾杨列 | 具有增强免疫力的营养强化剂及在保健休闲食品中的应用 |
CN109288058A (zh) * | 2018-12-05 | 2019-02-01 | 北京富乐喜科技有限公司 | 一种富勒烯增强正常细胞活性的保健品制剂及制备方法 |
CN110218717A (zh) * | 2019-05-22 | 2019-09-10 | 暨南大学 | 一种灵芝多糖的制备方法及其对超氧化物歧化酶干燥失活的保护作用 |
CN111066994A (zh) * | 2020-01-02 | 2020-04-28 | 广东轻工职业技术学院 | 一种解酒护肝功能饮料及其制备方法 |
CN111297963A (zh) * | 2020-04-10 | 2020-06-19 | 广东轻工职业技术学院 | 一种解酒护肝提取物、组合物及制备方法与应用 |
JP2021073987A (ja) * | 2019-11-12 | 2021-05-20 | 禅インターナショナル株式会社 | 栄養組成物 |
CN114246941A (zh) * | 2021-10-18 | 2022-03-29 | 广东昊邦医药健康有限责任公司 | 一种具有预防宿醉和解酒保肝的组合物及其应用 |
RU2807600C1 (ru) * | 2022-05-25 | 2023-11-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный университет генетики, биотехнологии и инженерии имени Н.И. Вавилова" | Антиоксидантный препарат для животных на основе водного раствора фуллерена С60, ресвератрола и альфа-липоевой кислоты |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101098684A (zh) * | 2004-12-07 | 2008-01-02 | 维生素C60生化学研究公司 | 自由基疾病预防治疗用组合物 |
CN105079033A (zh) * | 2015-08-13 | 2015-11-25 | 北京大学深圳研究院 | 一种复合型抗氧化组合物及其制备方法 |
CN105596368A (zh) * | 2016-02-01 | 2016-05-25 | 北京福纳康生物技术有限公司 | 一种富勒烯橄榄油组合物及其在治疗帕金森病中的应用 |
-
2017
- 2017-01-25 CN CN201710056575.9A patent/CN106692189A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101098684A (zh) * | 2004-12-07 | 2008-01-02 | 维生素C60生化学研究公司 | 自由基疾病预防治疗用组合物 |
CN105079033A (zh) * | 2015-08-13 | 2015-11-25 | 北京大学深圳研究院 | 一种复合型抗氧化组合物及其制备方法 |
CN105596368A (zh) * | 2016-02-01 | 2016-05-25 | 北京福纳康生物技术有限公司 | 一种富勒烯橄榄油组合物及其在治疗帕金森病中的应用 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108720018A (zh) * | 2018-06-27 | 2018-11-02 | 中科赛可瑞(大连)生物科技有限公司 | 一种含姜黄素的肝脏保健组合物及其方法和应用 |
CN108813436A (zh) * | 2018-07-10 | 2018-11-16 | 曾杨列 | 具有增强免疫力的营养强化剂及在保健休闲食品中的应用 |
CN109288058A (zh) * | 2018-12-05 | 2019-02-01 | 北京富乐喜科技有限公司 | 一种富勒烯增强正常细胞活性的保健品制剂及制备方法 |
CN110218717A (zh) * | 2019-05-22 | 2019-09-10 | 暨南大学 | 一种灵芝多糖的制备方法及其对超氧化物歧化酶干燥失活的保护作用 |
JP2021073987A (ja) * | 2019-11-12 | 2021-05-20 | 禅インターナショナル株式会社 | 栄養組成物 |
CN111066994A (zh) * | 2020-01-02 | 2020-04-28 | 广东轻工职业技术学院 | 一种解酒护肝功能饮料及其制备方法 |
CN111297963A (zh) * | 2020-04-10 | 2020-06-19 | 广东轻工职业技术学院 | 一种解酒护肝提取物、组合物及制备方法与应用 |
CN111297963B (zh) * | 2020-04-10 | 2021-11-26 | 广东轻工职业技术学院 | 一种解酒护肝提取物、组合物及制备方法与应用 |
CN114246941A (zh) * | 2021-10-18 | 2022-03-29 | 广东昊邦医药健康有限责任公司 | 一种具有预防宿醉和解酒保肝的组合物及其应用 |
RU2807600C1 (ru) * | 2022-05-25 | 2023-11-17 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский государственный университет генетики, биотехнологии и инженерии имени Н.И. Вавилова" | Антиоксидантный препарат для животных на основе водного раствора фуллерена С60, ресвератрола и альфа-липоевой кислоты |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106692189A (zh) | 一种保护肝脏的组合物 | |
Zhou et al. | The application of supercritical fluids technology to recover healthy valuable compounds from marine and agricultural food processing by-products: A review | |
KR102653883B1 (ko) | 복합 보충제 조성물 | |
Valero-Mendoza et al. | The whole pomegranate (Punica granatum. L), biological properties and important findings: A review | |
BRPI0621321A2 (pt) | formulações de suplemento dietético de multivitamìnico e multimineral natural para melhor absorção e utilização biológica | |
KR20130117660A (ko) | 토코트리에놀 조성물 | |
Kumar et al. | Role of nutraceuticals in health and disease prevention: a review | |
US8067045B2 (en) | Nutritional formulations and associated methods | |
Ganapathy et al. | Nutraceuticals: The new generation therapeutics | |
CN107105695A (zh) | 具有增强的抗氧化性的海洋卵磷脂制剂 | |
Islam et al. | Synergistic effects of carotenoids: Therapeutic benefits on human health | |
DE202011105533U1 (de) | Vitalstoff-Zusammensetzung gemäß asiatischer und mediterraner Ernährungskonzepte | |
US20030077336A1 (en) | Anti-inflammatory complex containing flaxseed oil | |
Rani et al. | Natural antioxidants and their intrinsic worth for wellbeing | |
CN107836533A (zh) | 一种可外用养颜护肤的食用紫苏籽精油 | |
Aleebrahim-Dehkordy et al. | Herbal antioxidants and kidney | |
JP2017178914A (ja) | 脳機能改善及び向上のための組成物 | |
Grad et al. | Generalized yellow skin caused by high intake of sea buckthorn | |
CN107224443A (zh) | 保护肝脏免于损伤及纤维化的虾红素蚬精护肝配方 | |
RU2602608C1 (ru) | Функциональные продукты питания и способ их получения | |
Riar et al. | Bioactive Compounds and Nutraceuticals: Classification, Potential Sources, and Application Status | |
Maurya et al. | Potentials of plant derived products for the treatment of skin disorders | |
Tyagi et al. | Unlocking Radiance: The Dynamic Duo of Flaxseeds and Aloe Vera in Hair Mask for Bioactive Brilliance | |
Niknamian | Introducing the Sorush Cancer Treatment Protocol (SCTP) | |
Phachonpai et al. | Cleistocalyx nervosum var. paniala fruit on neuropathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180425 Address after: 100064, room 5, 523, room 5, Haidian District trail Road, Beijing Applicant after: BEIJING FUNAKANG BIOTECHNOLOGY CO., LTD. Address before: 100064 north one street, Zhongguancun, Haidian District, Beijing, No. 2 Applicant before: Institute of Chemistry, Chinese Academy of Sciences Applicant before: BEIJING FUNAKANG BIOTECHNOLOGY CO., LTD. |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170524 |
|
RJ01 | Rejection of invention patent application after publication |